Agile Therapeutics, Inc.
AGRX · NASDAQ
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Revenue | $5,576 | $5,716 | $3,614 | $6,662 |
| % Growth | -2.4% | 58.2% | -45.8% | – |
| Cost of Goods Sold | $1,496 | $1,680 | $2,191 | $2,477 |
| Gross Profit | $4,080 | $4,036 | $1,423 | $4,185 |
| % Margin | 73.2% | 70.6% | 39.4% | 62.8% |
| R&D Expenses | $538 | $495 | $54 | $705 |
| G&A Expenses | $2,512 | $2,616 | $1,692 | $2,680 |
| SG&A Expenses | $6,288 | $6,298 | $5,421 | $7,480 |
| Sales & Mktg Exp. | $3,776 | $3,682 | $3,729 | $4,800 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $6,826 | $6,793 | $5,475 | $8,185 |
| Operating Income | -$2,746 | -$2,757 | -$4,052 | -$4,000 |
| % Margin | -49.2% | -48.2% | -112.1% | -60% |
| Other Income/Exp. Net | -$9,126 | $4,041 | -$418 | $3,201 |
| Pre-Tax Income | -$11,872 | $1,284 | -$4,470 | -$799 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,872 | $1,284 | -$4,470 | -$799 |
| % Margin | -212.9% | 22.5% | -123.7% | -12% |
| EPS | -1.73 | 0.28 | -1.51 | -0.27 |
| % Growth | -717.9% | 118.5% | -459.3% | – |
| EPS Diluted | -1.73 | 0.28 | -1.51 | -0.27 |
| Weighted Avg Shares Out | 6,856 | 4,632 | 2,964 | 2,950 |
| Weighted Avg Shares Out Dil | 6,856 | 4,632 | 2,964 | 2,950 |
| Supplemental Information | – | – | – | – |
| Interest Income | $28 | $23 | $17 | $13 |
| Interest Expense | $0 | $185 | $305 | $341 |
| Depreciation & Amortization | $0 | $103 | $100 | $98 |
| EBITDA | -$2,746 | $1,572 | -$4,065 | -$360 |
| % Margin | -49.2% | 27.5% | -112.5% | -5.4% |